NICE issues final appraisal document on ravulizumab for treating paroxysmal nocturnal haemoglobinuria (PNH)

In DRAFT guidance, NICE recommends ravulizumab as an option for treating PNH in adults with haemolysis with clinical symptoms suggesting high disease activity, or whose disease is clinically stable after having eculizumab for at least 6 months.

Source:

National Institute for Health and Care Excellence